tirzepatide 2022 December Blog Post: Tirzepatide, Worth the Weight? Tirzepatide: First Approval | Drugs

10.1210/en.2011-0174 63 KanoskiS

[163] In March 2023, a Novo Nordisk official said, based on a randomized, double-blind study (NCT03548935 [164] ) funded by the company, that people using semaglutide to lose weight regained two-thirds of their original weight loss one year (52 weeks) after discontinuing use of the drug

In the weight-loss trials around 4.9 to 5% of people were affected versus around 1% on placebo, and the FDA label classes alopecia as common (up to 1 in 10)

compounded semaglutide via 503A telehealth ($99 to $249)

Reacting to the proposals Dr Simon Cork, Senior Lecturer in Physiology, Anglia Ruskin University (ARU), said: The planned roll out of tirzepatide marks a key milestone in the future of obesity treatment

Semaglutides patent will also expire in 2026